Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,364.35

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,337.69 105
Education $26.66 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $2,364.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $13.2912/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307407 CMS
AstraZeneca Pharmaceuticals LP $19.7312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685745281 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9512/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700053459 CMS
E.R. Squibb & Sons, L.L.C. $9.8111/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300847 CMS
Janssen Biotech, Inc. $7.6611/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307403 CMS
Alexion Pharmaceuticals, Inc. $11.8811/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695597125 CMS
E.R. Squibb & Sons, L.L.C. $10.2711/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300843 CMS
Janssen Biotech, Inc. $15.5411/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307399 CMS
Novartis Pharmaceuticals Corporation $16.7311/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919905 CMS
AbbVie, Inc. $23.0511/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803755 CMS
E.R. Squibb & Sons, L.L.C. $10.1011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300837 CMS
Novartis Pharmaceuticals Corporation $20.4311/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919931 CMS
AstraZeneca Pharmaceuticals LP $81.0710/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685097061 CMS
AbbVie, Inc. $15.9810/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803745 CMS
E.R. Squibb & Sons, L.L.C. $12.6310/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300835 CMS
PFIZER INC. $90.2710/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673190719 CMS
AbbVie, Inc. $19.6610/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803727 CMS
Merck Sharp & Dohme Corporation $13.5810/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695789311 CMS
Novartis Pharmaceuticals Corporation $8.8910/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919897 CMS
PFIZER INC. $2.7510/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673198405 CMS
PFIZER INC. $1.7710/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673198407 CMS
Medtronic USA, Inc. $14.6809/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667736401 CMS
Janssen Biotech, Inc. $12.5709/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307393 CMS
Janssen Biotech, Inc. $124.9909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718859679 CMS
Incyte Corporation $125.0009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666276245 CMS
E.R. Squibb & Sons, L.L.C. $10.1709/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300823 CMS
Novartis Pharmaceuticals Corporation $5.6409/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919913 CMS
PFIZER INC. $3.1409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673016655 CMS
PFIZER INC. $1.6809/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673017515 CMS
E.R. Squibb & Sons, L.L.C. $6.7109/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300821 CMS
Janssen Biotech, Inc. $16.3409/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307389 CMS
TESARO, Inc. $87.8208/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675553859 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697406101 CMS
E.R. Squibb & Sons, L.L.C. $10.1308/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300817 CMS
Incyte Corporation $5.5808/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666276183 CMS
Merck Sharp & Dohme Corporation $14.9208/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695717161 CMS
Genentech USA, Inc. $15.4208/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681406553 CMS
Novartis Pharmaceuticals Corporation $7.4108/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919893 CMS
E.R. Squibb & Sons, L.L.C. $6.7008/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300815 CMS
Astellas Pharma US Inc $14.7808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655448515 CMS
JAZZ PHARMACEUTICALS INC. $21.9408/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684177971 CMS
Genentech USA, Inc. $17.8607/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681415405 CMS
Janssen Biotech, Inc. $15.5707/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307383 CMS
E.R. Squibb & Sons, L.L.C. $12.9907/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300809 CMS
Verastem, Inc. $88.8707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699790571 CMS
E.R. Squibb & Sons, L.L.C. $14.0407/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300801 CMS
E.R. Squibb & Sons, L.L.C. $0.7207/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300803 CMS
E.R. Squibb & Sons, L.L.C. $7.1107/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300811 CMS
AstraZeneca Pharmaceuticals LP $78.7006/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685555423 CMS
AbbVie, Inc. $18.4606/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803717 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TESARO, Inc. $1,250.00 09/26/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689413207
Principal investigator 1 Eli Lilly and Company $98.25 09/20/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654298193
Principal investigator 1 Eisai Inc. $257.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552753
Principal investigator 1 Eisai Inc. $257.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552755
Principal investigator 1 TESARO, Inc. $1,250.00 06/27/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689411931
Principal investigator 1 Eisai Inc. $257.00 04/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552743
Principal investigator 1 Genentech, Inc. $2,754.00 04/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681083745
Principal investigator 1 Genentech, Inc. $4,082.00 04/15/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681089413
Principal investigator 1 PFIZER INC. $1,250.00 04/09/2019 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 671633735
Principal investigator 1 Amgen Inc. $48,885.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675793821
Principal investigator 1 Eisai Inc. $312.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552741
Principal investigator 1 Eisai Inc. $312.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552745
Principal investigator 1 Eisai Inc. $281.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552747
Principal investigator 1 Eisai Inc. $257.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552749
Principal investigator 1 Eisai Inc. $281.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) No dispute reported 06/30/2026 702552751
Principal investigator 1 Eli Lilly and Company $218,650.00 02/12/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654299355
Principal investigator 1 PFIZER INC. $1,250.00 02/02/2019 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 671634195
Principal investigator 1 Eli Lilly and Company $158,312.65 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654295481
Principal investigator 1 TESARO, Inc. $1,250.00 01/15/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689409663
Recipient Eli Lilly and Company $1,341.00 01/08/2019 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654281871
Principal investigator 1 Eli Lilly and Company $268.62 01/03/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654298205